In breast cancer patients, bone is the most common site of metastases. Medical therapies are the basic therapy to prevent distant metastases and recurrence and to cure them. Radiotherapy has a primary role in pain relief, recalcification and stabilization of the bone, as well as the reduction of the risk of complications (e.g., bone fractures, spinal cord compression). Bisphosphonates, as potent inhibitors of osteoclastic-mediated bone resorption are a well-established, standard-of-care treatment option to reduce the frequency, severity and time of onset of the skeletal related events in breast cancer patients with bone metastases. Moreover bisphosphonates prevent cancer treatment-induced bone loss. Recent data shows the anti-tumor activity of bisphosphonates, in particular, in postmenopausal women and in older premenopausal women with hormone-sensitive disease treated with ovarian suppression. Pain is the most frequent symptom reported in patients with bone metastases, and its prevention and treatment must be considered at any stage of the disease. The prevention and treatment of bone metastases in breast cancer must consider an integrated multidisciplinary approach.
References
[1]
Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59, 225–249, doi:10.3322/caac.20006.
[2]
Coleman, R.E.; Rubens, R.D. The clinical course of bone metastases from breast cancer. Br. J. Cancer 1987, 55, 61–66, doi:10.1038/bjc.1987.13.
[3]
Coleman, R.E. Skeletal complications of malignancy. Cancer 1997, 80, 1588–1594, doi:10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G.
[4]
Hoskin, P.J. Bisphosphonates and radiation therapy for palliation of metastastic bone disease. Cancer Treat. Rev. 2003, 29, 321–327, doi:10.1016/S0305-7372(03)00013-6.
[5]
Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005, 365, 1687–1717, doi:10.1016/S0140-6736(05)66544-0.
[6]
Romond, E.; Perez, E.A.; Bryant, J.; Suman, V.J.; Geyer, C.E., Jr.; Davidson, N.E.; Tan-Chiu, E.; Martino, S.; Paik, S.; Kaufman, P.A. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353, 1673–1684, doi:10.1056/NEJMoa052122.
[7]
Perez, E.A.; Romond, E.H.; Suman, V.J.; Jeong, J.H.; Davidson, N.E.; Geyer, C.E., Jr.; Martino, S.; Mamounas, E.P.; Kaufman, P.A.; Wolmark, N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J. Clin. Oncol. 2011, 29, 3366–3373, doi:10.1200/JCO.2011.35.0868.
[8]
Perez, E.A.; Suman, V.J.; Davidson, N.E.; Gralow, J.R.; Kaufman, P.A.; Visscher, D.W.; Chen, B.; Ingle, J.N.; Dakhil, S.R.; Zujewski, J.; et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 2011, 29, 4491–4497, doi:10.1200/JCO.2011.36.7045.
[9]
Piccart, M.; Procter, M.; Leyland-Jones, B.; Goldhirsch, A.; Untch, M.; Smith, I.; Gianni, L.; Baselga, J.; Bell, R.; Jackisch, C. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. First result of HERA trial. N. Engl. J. Med. 2005, 353, 1659–1672, doi:10.1056/NEJMoa052306.
[10]
Gianni, L.; Dafni, U.; Gelber, R.D.; Azambuja, E.; Muehlbauer, S.; Goldhirsch, A.; Untch, M.; Smith, I.; Baselga, J.; Jackisch, C.; et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011, 12, 236–244, doi:10.1016/S1470-2045(11)70033-X.
[11]
Slamon, D.; Eiermann, W.; Robert, N.; Pienkowski, T.; Martin, M.; Press, M.; Mackey, J.; Glaspy, J.; Chan, A.; Pawlicki, M.; et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 2011, 365, 1273–1283, doi:10.1056/NEJMoa0910383.
[12]
Joensuu, H.; Kellokumpu-Lehtinen, P.L.; Bono, P.; Alanko, T.; Kataja, V.; Asola, R.; Utriainen, T.; Kokko, R.; Hemminki, A.; Tarkkanen, M.; et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 2006, 354, 809–820, doi:10.1056/NEJMoa053028.
[13]
Joensuu, H.; Bono, P.; Kataja, V.; Alanko, T.; Kokko, R.; Asola, R.; Utriainen, T.; Turpeenniemi-Hujanen, T.; Jyrkki？, S.; M？ykkynen, K.; et al. Fluorouracil, epirubicina, and cyclophosphamide with either docetaxel or vinorelbine, with and without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer trial. J. Clin. Oncol. 2009, 27, 5685–5692, doi:10.1200/JCO.2008.21.4577.
[14]
Spielmann, M.; Rochè, H.; Delozier, T.; Canon, J.L.; Romieu, G.; Bourgeois, H.; Extra, J.M.; Serin, D.; Kerbrat, P.; Machiels, J.P. Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trial. J. Clin. Oncol. 2009, 27, 6129–6134, doi:10.1200/JCO.2009.23.0946.
[15]
The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group; Forbes, J.F.; Cuzick, J.; Buzdar, A.; Howell, A.; Tobias, J.S.; Baum, M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-Month analysis of the ATAC trial. Lancet Oncol. 2008, 9, 45–53, doi:10.1016/S1470-2045(07)70385-6.
[16]
BIG 1-98 Collaborative Group; Mouridsen, H.; Giobbie-Hurder, A.; Goldhirsch, A.; Thürlimann, B.; Paridaens, R.; Smith, I.; Mauriac, L.; Forbes, J.; Price, K.N. Letrozole therapy alone or in sequence with tamoxifene in women with breast cancer. N. Engl. J. Med. 2009, 361, 766–776, doi:10.1056/NEJMoa0810818.
[17]
Dowsett, M.; Cuzick, J.; Ingle, J.; Coates, A.; Forbes, J.; Bliss, J.; Buyse, M.; Baum, M.; Buzdar, A.; Colleoni, M. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol. 2010, 28, 509–518, doi:10.1200/JCO.2009.23.1274.
[18]
LHRH-agonists in Early Breast Cancer Overview group; Cuzick, J.; Ambroisine, L.; Davidson, N.; Jakesz, R.; Kaufmann, M.; Regan, M.; Sainsbury, R. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormonereceptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007, 369, 1711–1723, doi:10.1016/S0140-6736(07)60778-8.
[19]
Klijn, J.G.; Beex, L.V.; Mauriac, L.; van Zijl, J.A.; Veyret, C.; Wildiers, J.; Jassem, J.; Piccart, M.; Burghouts, J.; Becquart, D. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study. J. Natl. Cancer Inst. 2000, 92, 903–911, doi:10.1093/jnci/92.11.903.
[20]
Peto, R.; Davies, C.; Godwin, J.; Gray, R.; Pan, H.C.; Clarke, M.; Cutter, D.; Darby, S.; McGale, P.; Taylor, C. Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379, 432–444, doi:10.1016/S0140-6736(11)61625-5.
[21]
De Laurentiis, M.; Cancello, G.; D’Agostino, D.; Giuliano, M.; Giordano, A.; Montagna, E.; Lauria, R.; Forestieri, V.; Esposito, A.; Silvestro, L. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J. Clin. Oncol. 2008, 26, 44–53, doi:10.1200/JCO.2007.11.3787.
[22]
Jones, S.E.; Savin, M.A.; Holmes, F.A.; O’Shaughnessy, J.A.; Blum, J.L.; Vukelja, S.; McIntyre, K.J.; Pippen, J.E.; Bordelon, J.H.; Kirby, R. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J. Clin. Oncol. 2006, 24, 5381–5387, doi:10.1200/JCO.2006.06.5391.
[23]
Jones, S.; Holmes, F.; O’Shaughnessy, J.; Blum, J.L.; Vukelja, S.J.; McIntyre, K.J.; Pippen, J.E.; Bordelon, J.H.; Kirby, R.L.; Sandbach, J. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-Year follow-up of US Oncology Research trial 9735. J. Clin. Oncol. 2009, 27, 1177–1183, doi:10.1200/JCO.2008.18.4028.
[24]
AIOM Guidelines on Breast Cancer 2012. Available online: http://www.aiom.com (accessed on 24 July 2013).
[25]
Body, J.J.; Diel, I.J.; Lichinitser, M.R.; Kreuser, E.D.; Dornoff, W.; Gorbunova, V.A.; Budde, M.; Bergstr？m, B.; MF 4265 Study Group. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. 2003, 14, 1399–1405, doi:10.1093/annonc/mdg367.
[26]
Kohno, N.; Aogi, K.; Minami, H.; Nakamura, S.; Asaga, T.; Iino, Y.; Watanabe, T.; Goessl, C.; Ohashi, Y.; Takashima, S. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J. Clin. Oncol. 2005, 23, 3314–3321, doi:10.1200/JCO.2005.05.116.
[27]
Lipton, A.; Theriault, R.L.; Hortobagyi, G.N.; Simeone, J.; Knight, R.D.; Mellars, K.; Reitsma, D.J.; Heffernan, M.; Seaman, J.J. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer 2000, 88, 1082–1090, doi:10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z.
[28]
Paterson, A.H.; Powles, T.J.; Kanis, J.A.; McCloskey, E.; Hanson, J.; Ashley, S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol. 1993, 11, 59–65.
[29]
Rosen, L.S.; Gordon, D.; Kaminski, M.; Howell, A.; Belch, A.; Mackey, J.; Apffelstaedt, J.; Hussein, M.A.; Coleman, R.E.; Reitsma, D.J.; et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98, 1735–1744, doi:10.1002/cncr.11701.
[30]
Saarto, T.; Blomqvist, C.; Valimaki, M.; Makela, P.; Sarna, S.; Elomaa, I. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br. J. Cancer 1997, 75, 602–605, doi:10.1038/bjc.1997.105.
[31]
Van Poznak, C.H.; Temin, S.; Yee, G.C.; Janjan, N.A.; Barlow, W.E.; Biermann, J.S.; Bosserman, L.D.; Geoghegan, C.; Hillner, B.E.; Theriault, R.L.; et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J. Clin. Oncol. 2011, 29, 1221–1227, doi:10.1200/JCO.2010.32.5209.
[32]
Fizazi, K.; Carducci, M.; Smith, M.; Dami？o, R.; Brown, J.; Karsh, L.; Milecki, P.; Shore, N.; Rader, M.; Wang, H.; et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistent prostate cancer: A randomized, double-blind study. Lancet 2011, 377, 813–822, doi:10.1016/S0140-6736(10)62344-6.
[33]
Stopeck, A.T.; Lipton, A.; Body, J.J.; Steger, G.G.; Tonkin, K.; de Boer, R.H.; Lichinitser, M.; Fujiwara, Y.; Yardley, D.A.; Viniegra, M.; et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J. Clin. Oncol. 2010, 28, 5132–5139, doi:10.1200/JCO.2010.29.7101.
[34]
Amadori, D.; Aglietta, M.; Alessi, B.; Gianni, L.; Ibrahim, T.; Farina, G.; Gaion, F.; Bertoldo, F.; Santini, D.; Rondena, R.; et al. Efficacy and safety of 12-wwkly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): A phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol. 2013, 14, 663–670, doi:10.1016/S1470-2045(13)70174-8.
[35]
Coleman, R.E.; Major, P.; Lipton, A.; Brown, J.E.; Lee, K.A.; Smith, M.; Saad, F.; Zheng, M.; Hei, Y.J.; Seaman, J.; et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronicacid. J. Clin. Oncol. 2005, 23, 4925–4935, doi:10.1200/JCO.2005.06.091.
[36]
American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 2007, 65, 369–376, doi:10.1016/j.joms.2006.11.003.
[37]
Ripamonti, C.I.; Maniezzo, M.; Campa, T.; Fagnoni, E.; Brunelli, C.; Saibene, G.; Bareggi, C.; Ascani, L.; Cislaghi, E. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann. Oncol. 2009, 20, 137–145.
[38]
American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaw—2009 Update. Available online: http://www.aaoms.org/docs/position_papers/bronj_update.pdf (accessed on 14 June 2010).
[39]
Ripamonti, C.I.; Cislaghi, E.; Mariani, L.; Maniezzo, M. Efficay and safety of medical ozone (O3) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates. Preliminary results of a phase I–II study. Oral Oncol. 2011, 47, 185–190.
[40]
Ripamonti, C.; Maniezzo, M.; Pessi, M.A.; Cislaghi, E.; Mariani, L.; Boldini, S. Efficacy and tolerability of medical ozone (O3) gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates—Preliminary data: Medical ozone gas insufflation in treating ONJ lesions. J. Bone Oncol. 2012, 1, 81–87.
[41]
Gnant, M.; Dubsky, P.; Hadji, P. Bisphosphonates: Prevention of bone metastases in breast cancer. Recent Results Cancer Res. 2012, 192, 65–91.
[42]
Lustberg, M.B.; Reinbolt, R.E.; Shapiro, C.L. Bone health in adult cancer survivorship. J. Clin. Oncol. 2012, 30, 3665–3674.
[43]
Winter, M.C.; Coleman, R.E. Bisphosphonates in the adjuvant treatment of breast cancer. Clin. Oncol. 2013, 25, 135–145.
[44]
Coleman, R.E. Adjuvant bone-targeted therapy to prevent metastasis: Lessons from the AZURE study. Curr. Opin. Support. Palliat. Care 2012, 6, 322–329.
[45]
Young, R.J.; Coleman, R.E. Zoledronic acid to prevent and treat cancer metastasis: New prospects for an old drug. Future Oncol. 2013, 9, 633–643.
[46]
Powles, T.; Paterson, S.; Kanis, J.A.; McCloskey, E.; Ashley, S.; Tidy, A.; Rosenqvist, K.; Smith, I.; Ottestad, L.; Legault, S.; et al. Randomized placebo-controlled trial of clodronate in patients with primary operable breast cancer. J. Clin. Oncol. 2002, 20, 3219–3224.
[47]
Saarto, T.; Blomqvist, C.; Virkkunen, P.; Elomaa, I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node positive breast cancer patients: 5-Year results of a randomized controlled trial. J. Clin. Oncol. 2001, 19, 10–17.
[48]
Diel, I.J.; Jaschke, A.; Solomayer, E.F.; Gollan, C.; Bastert, G.; Sohn, C.; Schuetz, F. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow—A long term follow-up. Ann. Oncol. 2008, 19, 2007–2011.
[49]
Gnant, M.; Mlineritsch, B.; Schipping, W.; Luschin-Ebengreuth, G.; P？stlberger, S.; Menzel, C.; Jakesz, R.; Seifert, M.; Hubalek, M.; Bjelic-Radisic, V.; et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 2009, 360, 679–691, doi:10.1056/NEJMoa0806285.
[50]
Gnant, M.; Mlineritsch, B.; Schippinger, W.; Luschin-Ebengreuth, G.; P？stlberger, S.; Menzel, C.; Jakesz, R.; Seifert, M.; Hubalek, M.; Bjelic-Radisic, V.; et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-Month follow-up from the ABCSG-12 randomized trial. Lancet Oncol. 2011, 12, 631–641.
[51]
Gnant, M.; Mlineritsch, B.; Stoeger, H.; Luschin-Ebengreuth, G.; Heck, D.; Menzel, C.; Jakesz, R.; Seifert, M.; Hubalek, M.; Pristauz, G.; et al. Long-term follow-up in ABCSG-12: Significant improved overall survival with adjuvant zoledronic acid in pre-menopausal patients with endocrine-receptor-positive early breast cancer. Cancer Res. 2011, 71, S1–S2.
[52]
Coleman, R.E.; Marshall, H.; Cameron, D.; Dodwell, D.; Burkinshaw, R.; Keane, M.; Gil, M.; Houston, S.J.; Grieve, R.J.; Barrett-Lee, P.J.; et al. Breast cancer adjuvant therapy with zoledronic acid. N. Engl. J. Med. 2011, 365, 1396–1405, doi:10.1056/NEJMoa1105195.
[53]
Eidtmann, H.; de Boer, R.; Bundred, N.; Llombart-Cussac, A.; Davidson, N.; Neven, P.; von Minckwitz, G.; Miller, J.; Schenk, N.; Coleman, R. Efficacy of zoledronic acid in postmenopausal women with early breast cancer adjuvant letrozole: 36-Month results of the ZO-FAST study. Ann. Oncol. 2010, 21, 2188–2194, doi:10.1093/annonc/mdq217.
[54]
Ripamonti, C.; Santini, D.; Maranzano, E.; Berti, M.; Roila, F.; ESMO Guidelines Working Group. Management of cancer pain: ESMO clinical practice guidelines. Ann. Oncol. 2012, 23, 139–154, doi:10.1093/annonc/mds355.
[55]
Word Health Organization. World Health Organization Cancer Pain Relief Geneva; Word Health Organization: Geneve, Switzerland, 1986.
[56]
Word Health Organization. World Health Organization Cancer Pain Relief, 2nd Geneva ed.; Word Health Organization: Geneve, Switzerland, 1996.
[57]
Mercadante, S.; Radbruch, L.; Caraceni, A.; Cherny, N.; Kaasa, S.; Nauck, F.; Ripamonti, C.; de Conno, F. Episodic breakthrough pain: Consensus conference of an export working group of the European Association for Palliative Care. Cancer 2002, 94, 832–839, doi:10.1002/cncr.10249.
[58]
Wong, R.K.S.; Wiffen, P.J. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst. Rev. 2002, 2, doi:10.1002/14651858.CD002068.
[59]
Cleeland, C.S.; Body, J.J.; Stopeck, A.; von Moos, R.; Fallowfield, L.; Mathias, S.D.; Patrick, D.L.; Clemons, M.; Tonkin, K.; Masuda, N.; et al. Pain outcomes in patients with advanced breast cancer and bone metastases: Results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 2013, 119, 832–838, doi:10.1002/cncr.27789.
[60]
Wu, J.S.; Wong, R.K.; Lloyd, N.S.; Johnston, M.; Bezjak, A.; Whelan, T.; Supportive Care Guidelines Group of Cancer Care Ontario. Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases—An evidence-based practice guideline. BMC Cancer 2004, 4, doi:10.1186/1471-2407-4-71.
[61]
Koswig, S.; Budach, V. Remineralization and pain relief in bone metastases after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study. Strahlenther. Onkol. 1999, 175, 500–508, doi:10.1007/s000660050061.
[62]
Chow, E.; Harris, K.; Fan, G.; Tsao, M.; Sze, W.M. Palliative radiotherapy trials for bone metastases: A systematic review. J. Clin. Oncol. 2007, 10, 1423–1436.
[63]
Fairchild, A.; Barnes, E.; Ghosh, S.; Ben-Josef, E.; Roos, D.; Hartsell, W.; Holt, T.; Wu, J.; Janjan, N.; Chow, E. International pattern of practice in palliative radiotherapy for painful bone metastases: Evidence-based practice? Int. J. Radiat. Oncol. Biol. Phys. 2009, 75, 1501–1510, doi:10.1016/j.ijrobp.2008.12.084.
[64]
Lutz, S.; Berk, L.; Chang, E.; Lutz, S.; Berk, L.; Chang, E.; Chow, E.; Hahn, C.; Hoskin, P.; Howell, D.; et al. Palliative radiotherapy for bone metastases: An ASTRO evidence-based guideline. Int. J. Radiat. Oncol. Biol. Phys. 2011, 79, 965–976, doi:10.1016/j.ijrobp.2010.11.026.
[65]
Howell, D.D.; James, J.L.; Hartsell, W.F.; Suntharalingam, M.; Machtay, M.; Suh, J.H.; Demas, W.F.; Sandler, H.M.; Kachnic, L.A.; Berk, L.B. Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases-equivalent efficacy, less toxicity, more convenient. Cancer 2013, 119, 888–896, doi:10.1002/cncr.27616.
[66]
Van der Linden, Y.M.; Lok, J.J.; Steenland, E.; Martijn, H.; van Houwelingen, H.; Marijnen, C.A.; Leer, J.W. Single fraction radiotherapy is efficacious: A further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59, 528–537, doi:10.1016/j.ijrobp.2003.10.006.
[67]
Chow, E.; Hoskin, P.J.; Wu, J.; Roos, D.; van der Linden, Y.; Hartsell, W.; Vieth, R.; Wilson, C.; Pater, J. A phase III international randomised trial comparing single with multiple fractions for re-irradiation of painful bone metastases: National Cancer Institute of Canada Clinical Trials Group (NCICCTG) SC20. Clin.Oncol. 2006, 18, 125–128, doi:10.1016/j.clon.2005.11.014.
[68]
Huisman, M.; van den Bosch, M.A.; Wijlemans, J.W.; van Vulpen, M.; van der Linden, Y.M.; Verkooijen, H.M. Effectiveness of reirradiation for painful bonemetastases: A systematic review and meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 2012, 84, 8–14, doi:10.1016/j.ijrobp.2011.10.080.
[69]
Cai, B.; Nickman, N.A.; Gaffney, D.K. The role of palliative external beam radiation therapy in boney metastases pain management. J. Pain Palliat. Care Pharmacother. 2013, 27, 28–34, doi:10.3109/15360288.2012.757267.
[70]
Dennis, K.; Makhani, L.; Zeng, L.; Lam, H.; Chow, E. Single fraction conventional external beam radiation therapy for bone metastases: A systematic review of randomised controlled trials. Radiother.Oncol. 2013, 106, 5–14, doi:10.1016/j.radonc.2012.12.009.
[71]
Souchon, R.; Wenz, F.; Sedlmayer, F.; Budach, W.; Dunst, J.; Feyer, P.; Haase, W.; Harms, W.; Sautter-Bihl, M.L.; Sauer, R. DEGRO practice guidelines for palliative radiotherapy of metastatic breast cancer: Bone metastases and metastatic spinal cord compression (MSCC). Strahlenther. Onkol. 2009, 185, 417–424, doi:10.1007/s00066-009-2044-2.
[72]
Falkmer, U.; J？rhult, J.; Wers？ll, P.; Cavallin-St？hl, E. A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol. 2003, 42, 620–633, doi:10.1080/02841860310014895.
[73]
Kouloulias, E.V.; Kouvaris, R.J.; Antypas, C.; Mystakidou, K.; Matsopoulos, G.; Uzunoglu, C.N.; Moulopoulos, A.; Vlahos, J.L. An intra-patient dose escalation study of disodium pamidronate plus radiotherapy versus radiotherapy alone for the treatment of osteolytic metastasis. Monitoring of recalcification using image-processing. Strahlenther. Onkol. 2003, 179, 471–479.
[74]
Maranzano, E.; Trippa, F.; Chirico, L.; Basagni, M.L.; Rossi, R. Management of metastatic spinal cord compression. Tumori 2003, 89, 469–475.
[75]
Loblaw, D.A.; Mitera, G.; Ford, M.; Laperriere, N.J. A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord compression. Int.J.Radiat.Oncol.Biol.Phys. 2012, 84, 312–317, doi:10.1016/j.ijrobp.2012.01.014.
[76]
Byrne, T.N. Spinal cord compression from epidural metastases. N. Engl. J. Med. 1992, 327, 614–619, doi:10.1056/NEJM199208273270907.
[77]
Rades, D.; Heidenreich, F.; Karstens, J.H. Final results of a prospective study of the prognostic value of the time to develop motor deficits before irradiation in metastatic spinal cord compression. Int. J. Radiat. Oncol. Biol. Phys. 2002, 53, 975–979, doi:10.1016/S0360-3016(02)02819-5.
[78]
Patchell, R.A.; Tibbs, P.A.; Regine, W.F.; Payne, R.; Saris, S.; Kryscio, R.J.; Mohiuddin, M.; Young, B. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: A randomised trial. Lancet 2005, 366, 643–648.
[79]
Maranzano, E.; Bellavita, R.; Rossi, R.; de Angelis, V.; Frattegiani, A.; Bagnoli, R.; Mignogna, M.; Beneventi, S.; Lupattelli, M.; Ponticelli, P.; et al. Short-course versus split-course radiotherapy in metastatic spinal cord compression: Results of a phase III, randomized, multicenter trial. J. Clin. Oncol. 2005, 23, 3358–3365, doi:10.1200/JCO.2005.08.193.
[80]
Maranzano, E.; Trippa, F.; Casale, M.; Costantini, S.; Lupattelli, M.; Bellavita, R.; Marafioti, L.; Pergolizzi, S.; Santacaterina, A.; Mignogna, M.; et al. 8 Gy single-dose radiotherapy is effective in metastatic spinal cord compression: Results of a phase III randomized multicentre Italian trial. Radiother. Oncol. 2009, 93, 174–179, doi:10.1016/j.radonc.2009.05.012.
[81]
Prewett, S.; Venkitaraman, R. Metastatic spinal cord compression: Review of the evidence for a radiotherapy dose fractionation schedule. Clin. Oncol. 2010, 22, 222–230, doi:10.1016/j.clon.2010.01.006.
[82]
Holt, T.; Hoskin, P.; Maranzano, E.; Sahgal, A.; Schild, S.; Ryu, S.; Loblaw, A. Malignant epidural spinal cord compression: The role of external beam radiotherapy. Curr. Opin. Support. Palliat. Care 2012, 6, 103–108, doi:10.1097/SPC.0b013e32834de701.
[83]
Rades, D.; Lange, M.; Veninga, T.; Stalpers, L.J.; Bajrovic, A.; Adamietz, I.A.; Rudat, V.; Schild, S.E. Final results of a prospective study comparing the local control of short-course and long-course radiotherapy for metastatic spinal cord compression. Int. J. Radiat. Oncol. Biol.Phys. 2011, 79, 524–530, doi:10.1016/j.ijrobp.2009.10.073.
[84]
Sorensen, S.; Helweg-Larsen, S.; Mouridsen, H.; Hansen, H.H. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: A randomized trial. Eur. J. Cancer 1994, 1, 22–27.
[85]
Maranzano, E.; Latini, P.; Beneventi, S.; Perrucci, E.; Panizza, B.M.; Aristei, C.; Lupattelli, M.; Tonato, M. Radiotherapy without steroids in selected metastatic spinal cord compression patients. A phase II trial. Am. J. Clin. Oncol. 1996, 19, 179–184, doi:10.1097/00000421-199604000-00018.
[86]
Sciuto, R.; Festa, A.; Pasqualoni, R.; Semprebene, A.; Rea, S.; Bergomi, S.; Maini, C.L. Metastatic bone pain palliation with 89-Sr and 186-Re-HeDP in breast cancer patients. Breast Cancer Res. Treat. 2001, 66, 101–109, doi:10.1023/A:1010658522847.
[87]
Leondi, A.H.; Souvatzoglou, M.A.; Rapti, A.S.; Leontopoulou, S.A.; Papadaki, E.K.; Datseris, E.I.; Anagnostopoulou, U.S.; Zerva, C.J. Palliative treatment of painful disseminated bone metastases with 186Rhenium-HeDP in patients with lung cancer. J. Nucl. Med. 2004, 48, 211–219.
[88]
Han, S.H.; de Klerk, J.M.; Tan, S.; van Het Schip, A.D.; Derksen, B.H.; van Dijk, A.; Kruitwagen, C.L.; Blijham, G.H.; van Rijk, P.P.; Zonnenberg, B.A. The PLACORHeN study: A double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. J. Nucl. Med. 2002, 43, 1150–1156.
[89]
Roqué, I.; Figuls, M.; Martinez-Zapata, M.J.; Scott-Brown, M.; Alonso-Coello, P. Radioisotopes for metastatic bone pain. Cochrane Database Syst. Rev. 2011, 7, doi:10.1002/14651858.CD003347.
[90]
Saghal, A.; Larson, D.A.; Chang, E.L. Stereotactic body radiosurgery for spinal metastases: A critical review. Int. J. Radiat. Oncol. Biol. Phys. 2008, 71, 652–665, doi:10.1016/j.ijrobp.2008.02.060.
[91]
Regine, W.; Ryu, S.; Chang, E.L. Spine radiosurgery for spinal cord compression: The radiation oncologist’s perspective. J. Radiosurg. SBRT 2011, 1, 55–61.
[92]
Chang, E.L.; Shiu, A.S.; Mendel, E.; Mathews, L.A.; Mahajan, A.; Allen, P.K.; Weinberg, J.S.; Brown, B.W.; Wang, X.S.; Woo, S.Y.; et al. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J. Neurosurg. Spine 2007, 7, 151–160, doi:10.3171/SPI-07/08/151.
[93]
Attar, S.; Steffner, R.J.; Avedian, R.; Hussain, W.M. Surgicalintervention of non-vertebral osseousmetastasis. Cancer Control 2012, 19, 113–121.
[94]
Townsend, P.W.; Rosenthal, H.G.; Smalley, S.R.; Cozad, S.C.; Hassanein, R.E. Impact of postoperative radiation therapy and other perioperative factors on outcome after orthopedic stabilization of impending or pathologic fractures due to metastatic disease. J. Clin. Oncol. 1994, 12, 2345–2350.
[95]
Fourney, D.R.; Schomer, D.F.; Nader, R.; Chlan-Fourney, J.; Suki, D.; Ahrar, K.; Rhines, L.D.; Gokaslan, Z.L. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J. Neurosurg. 2003, 98, 21–30, doi:10.3171/jns.2003.98.1.0021.
[96]
Pflugmacher, R.; Taylor, R.; Agarwal, A.; Melcher, I.; Disch, A.; Haas, N.P.; Klostermann, C. Balloon kyphoplasty in the treatment of metastatic disease of the spine: A 2-year prospective evaluation. Eur. Spine J. 2008, 17, 1042–1048, doi:10.1007/s00586-008-0701-2.
[97]
Gerszten, P.C.; Germanwala, A.; Burton, S.; Welch, W.C.; Ozhasoglu, C.; Vogel, W. Combination kyphoplasty and spinal radiosurgery: A new treatment paradigm for pathological fractures. J. Neurosurg. Spine 2005, 3, 296–301, doi:10.3171/spi.2005.3.4.0296.
[98]
Ashamalla, H.; Cardoso, E.; Macedon, M.; Guirguis, A.; Weng, L.; Ali, S.; Mokhtar, B.; Ashamalla, M.; Panigrahi, N. Phase I trial of Vertebral Intracavitary Cement and Samarium (VICS): Novel technique for treatment of painful vertebral metastasis. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75, 836–842, doi:10.1016/j.ijrobp.2008.11.060.
[99]
Fourney, D.R.; Abi-Said, D.; Lang, F.F.; McCutcheon, I.E.; Gokaslan, Z.L. Use of pedicle screw fixation in the management of malignant spinal disease: Experience in 100 consecutive procedures. J. Neurosurg. 2001, 94, 25–37.
[100]
Gokaslan, Z.L.; York, J.E.; Walsh, G.L.; McCutcheon, I.E.; Lang, F.F.; Putnam, J.B., Jr.; Wildrick, D.M.; Swisher, S.G.; Abi-Said, D.; Sawaya, R. Transthoracic vertebrectomy for metastatic spinal tumors. J. Neurosurg. 1998, 89, 599–609, doi:10.3171/jns.1998.89.4.0599.
[101]
Klimo, P., Jr.; Thompson, C.J.; Kestle, J.R.; Schmidt, M.H. A meta-analysis of surgery versus conventional radiotherapy for the treatment of metastatic spinal epidural disease. Neuro Oncol. 2005, 7, 64–76, doi:10.1215/S1152851704000262.
[102]
Young, R.F.; Post, E.M.; King, G.A. Treatment of spinal epidural metastases: Randomized prospective comparison of laminectomy and radiotherapy. J. Neurosurg. 1980, 53, 741–748, doi:10.3171/jns.1980.53.6.0741.
